Landos Biopharma, Inc. (LABP)
| Market Cap | 152.62M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -29.67M |
| Shares Out | 41.93M |
| EPS (ttm) | -0.97 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 69,877 |
| Open | 3.30 |
| Previous Close | 3.39 |
| Day's Range | 3.03 - 3.64 |
| 52-Week Range | 2.78 - 16.99 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 26.08 (+616.5%) |
| Earnings Date | n/a |
About LABP
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate in development is BT-11, an oral lanthionine synthetase C-like protein 2 (LANCL2) agonist for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and inflammatory bowel diseases. The company also develops NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1, a mitochondria-associated receptor associated with the modulation of inflammatory ...
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for LABP stock is "Buy." The 12-month stock price forecast is 26.08, which is an increase of 616.48% from the latest price.
News
Landos Biopharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Enhancing Focus on High-Impact Clinical-Stage Programs to Ensure Optimal Path to Commercialization
Should You Buy Landos Biopharma (LABP) Ahead of Earnings?
Landos Biopharma (LABP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Landos Biopharma Announces Leadership Transition
Josep Bassaganya-Riera Steps Down as Chairman, President and CEO
Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Rheumatoid Arthritis
Phase 1 trial is underway with topline results expected in the first half of 2022
Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Systemic Lupus Erythematosus
Phase 1 trial initiation expected before yearend with topline results in 1H 2022
Landos Biopharma Announces Publication in Scientific Reports of Novel Preclinical Findings Demonstrating Omilancor's ...
BLACKSBURG, Va., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to discover and deve...
Landos Biopharma to Collaborate on a Phase 2 Study of Omilancor in Crohn's Disease with the Icahn School of Medicine ...
Second Phase 2 trial of omilancor in Crohn's disease (CD), expected to initiate in 2021
Landos Biopharma to Participate in Two Upcoming Investor Conferences in September
BLACKSBURG, Va., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel or...
Landos Biopharma Announces Research Collaboration into the NLRX1 Pathway in Multiple Sclerosis with Johns Hopkins Uni...
BLACKSBURG, Va., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel ora...
Landos Biopharma to Participate in Upcoming Investor Events
BLACKSBURG, Va., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel ora...
Landos Biopharma Reports Second Quarter 2021 Financial Results and Provides Business Updates
Following the recent positive End-of-Phase 2 meeting with the FDA, Landos initiated global pivotal Phase 3 clinical trial site feasibility studies of omilancor in ulcerative colitis (UC)
Landos Biopharma to Present at the Raymond James Virtual Human Health Innovation Conference
BLACKSBURG, Va., June 14, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE Advanced A.I. platform to discover and devel...
Landos Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for Omilancor in Mild-to-Moderate ...
The FDA clears the path to initiate the PACIFY I and II global registration studies in Mild-to-Moderate Active UC patients representing the potential for a broad product label for Omilancor The FDA clea...
Landos Biopharma to Present at the Jefferies Virtual Healthcare Conference
BLACKSBURG, Va., May 25, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE A.I. platform to discover and develop novel o...
Landos Biopharma Announces the Appointment of Tim M. Mayleben to its Board of Directors
BLACKSBURG, Va., May 19, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients w...
Landos Biopharma, LianBio Ink Licensing Pact For Omilancor & NX-13 in Greater China
Landos Biopharma Inc (NASDAQ: LABP) and LianBio have announced an exclusive collaboration and license agreement for the development and commercialization of omilancor and NX-13 in Greater China (mainlan...
Landos Biopharma Reports First Quarter 2021 Financial Results and Provides Business Updates
Completed initial public offering of common stock, raising approximately $100 million in gross proceeds
Landos Biopharma to Present Two Late-Breaking Presentations on Therapeutic Potential of Omilancor and PX-69 at the 20...
BLACKSBURG, Va., April 26, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with...
Landos Biopharma Announces the Appointment of Tiago Girão to its Board of Directors
BLACKSBURG, Va., April 13, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with...
Landos Biopharma Stock Is Trading Higher On Initiating Early-Stage Study With Omilancor For Esophagus Inflammation
The FDA has signed off Landos Biopharma's (NASDAQ: LABP) Investigational New Drug application for omilancor (BT-11) for the treatment of Eosinophilic Esophagitis (EoE). Landos expects to initiate patien...
Landos Biopharma Announces FDA Clearance of IND Application for Omilancor for the Treatment of Eosinophilic Esophagitis
Third potential indication for omilancor (BT-11), a first-in-class candidate for the treatment of autoimmune diseases Third potential indication for omilancor (BT-11), a first-in-class candidate for the...
Landos Biopharma Announces Positive Results from a Phase 1 Study of NX-13 in Healthy Volunteers
NX-13 was well tolerated with no reported serious adverse events
Landos Biopharma to Participate in the SVB Leerink 10th Annual Global Healthcare Conference
BLACKSBURG, Va., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma (Nasdaq: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with ...
Landos Biopharma Announces Pricing of Initial Public Offering
BLACKSBURG, Va., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune dise...